(Q37782472)

reason for preferred rank

23 August 2017

title

Cutaneous lupus erythematosus: Update of therapeutic options (English)

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

23 June 2024

Cutaneous lupus erythematosus: update of therapeutic options part I (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739095

cutaneous lupus erythematosus

23 June 2024

main subject

1 reference

Annegret Kuhn

1

1 reference

23 August 2017

Vincent Ruland

2

1 reference

23 August 2017

Gisela Bonsmann

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

23 August 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0190962210006997?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

https://api.elsevier.com/content/article/PII:S0190962210006997?httpAccept=text/plain

23 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Journal of the American Academy of Dermatology

23 June 2024

published in

1 reference

23 August 2017

volume

65

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

e179-93

1 reference

Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus.

23 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations

23 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Phototesting in lupus erythematosus: a 15-year experience

23 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Sun-induced life-threatening lupus nephritis

23 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

An exacerbation of SLE after visiting a tanning salon

23 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Implication for photosensitive patients of ultraviolet A exposure in vehicles

23 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Broad-spectrum photoprotection: the roles of tinted auto windows, sunscreens and browning agents in the diagnosis and treatment of photosensitivity

23 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet a emissions from a photocopier

23 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus

23 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Analysis of compact fluorescent lights for use by patients with photosensitive conditions

23 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products

23 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The relation between sun protection factor and amount of suncreen applied in vivo

23 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test

23 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Use of sunscreens to protect against ultraviolet-induced lupus erythematosus

23 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus

23 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus

23 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cutaneous lupus erythematosus

23 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Topical calcineurin inhibitors in cutaneous lupus erythematosus

23 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The use of topical calcineurin inhibitors in lupus erythematosus: an overview.

23 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation

23 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases

23 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Topical treatment with tacrolimus in lupus erythematosus tumidus

23 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus

23 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus

23 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study.

23 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

23 June 2024

Pimecrolimus: a review.

36

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Pimecrolimus 1% cream for cutaneous lupus erythematosus

23 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus

23 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Treatment of localized discoid lupus erythematosus with tazarotene

23 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cutaneous lupus treated with topical tretinoin: a case report

23 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod

23 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%.

23 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream

23 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Successful treatment of discoid lupus erythematosus with argon laser

23 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Koebner phenomenon in lupus erythematosus with special consideration of clinical findings

23 June 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Successful treatment of chronic discoid lupus erythematosus with argon laser

23 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Laser treatment of discoid lupus (case report).

23 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Carbon dioxide laser resurfacing of facial scarring secondary to chronic discoid lupus erythematosus

23 June 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cutaneous lupus erythematosus-treatment with pulsed dye laser

23 June 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus

23 June 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Discoid lupus erythematosus treated with cryotherapy

23 June 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Socioeconomic factors in lupus erythematosus

23 June 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus

23 June 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus

23 June 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial

23 June 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

UV hardening therapy: a novel intervention in patients with photosensitive cutaneous lupus erythematosus

23 June 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies

23 June 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine

23 June 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Systemic treatment of cutaneous lupus erythematosus

23 June 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

New concepts in antimalarial use and mode of action in dermatology

23 June 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Antimalarial agents: closing the gate on Toll-like receptors?

23 June 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Hydroxychloroquine: the cornerstone of lupus therapy

23 June 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Treatment of lupus erythematosus with mepacrine

23 June 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Antimalarials in the management of discoid and systemic lupus erythematosus

23 June 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination

23 June 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Is there a role for quinacrine (Atabrine) in the new millennium?

23 June 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

23 June 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Antimalarials for children: indications, toxicities, and guidelines

23 June 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary

23 June 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Antimalarial drug-induced aquagenic-type pruritus in patients with lupus

23 June 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Desensitization to hydroxychloroquine: alternative interpretations

23 June 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Fatal toxic epidermal necrolysis associated with hydroxychloroquine

23 June 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis

23 June 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice

23 June 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology

23 June 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Detecting chloroquine retinopathy: electro-oculogram versus colour vision

23 June 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The dilemma of hydroxychloroquine screening: new information from the multifocal ERG.

23 June 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy

23 June 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients

23 June 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cardiomyopathy related to antimalarial therapy with illustrative case report

23 June 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine

23 June 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine

23 June 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus

23 June 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus

23 June 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus

23 June 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.

23 June 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Dapsone in the treatment of cutaneous lupus erythematosus.

23 June 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Smoking as a trigger for inflammatory rheumatic diseases

23 June 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Tobacco smoking and autoimmune rheumatic diseases

23 June 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Report of an association between discoid lupus erythematosus and smoking

23 June 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Association between Discoid Lupus erythematosus and Cigarette Smoking

23 June 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency

23 June 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

The effects of lysosomotropic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes

23 June 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cigarette smoking and clinically significant drug interactions

23 June 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment

23 June 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus

23 June 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus

23 June 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking

23 June 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus

23 June 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients

23 June 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

Pulse methylprednisolone therapy for persistent subacute cutaneous lupus

23 June 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2010.06.018

23 June 2024

Identifiers

1 reference

23 August 2017

1 reference